Moderna Inc. (MRNA)
Moderna Posts Wider-Than-Expected Q4 Loss, 2025 Sales Guide Disappoints
Moderna reported a wider loss than expected for the fourth quarter on Friday morning, and the drugmaker's sales forecast for 2025 also came in below estimates.
MRNA Reiterates Guidance, Bird Flu Vaccine in Pipeline
Jenny Horne examines earnings figures from biotech giant Moderna (MRNA). The company reported a 4Q loss as it continues to reposition itself following monumental gains during the heights of the COVID-19 pandemic.
Moderna (MRNA) Reports Q4 Loss, Tops Revenue Estimates
Moderna (MRNA) came out with a quarterly loss of $2.50 per share versus the Zacks Consensus Estimate of a loss of $2.69. This compares to earnings of $0.55 per share a year ago.
Moderna beats on revenue but loses more than expected as it scales down manufacturing
Moderna beat on fourth-quarter revenue but lost more than expected for the period, as the biotech company continues to slash costs and see lower demand for its Covid vaccine. It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the rapid decline of its once-booming Covid business.
Moderna's wider-than-expected loss and soft guidance weigh on battered stock
COVID-19 vaccine sales topped consensus but RSV sales remain modest
Moderna posts bigger loss than expected as vaccine maker scales down manufacturing
Moderna reported a bigger-than-expected quarterly loss on Friday, hit by a charge related to its efforts to scale down manufacturing amid weakening demand for its COVID-19 vaccine.
Moderna Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Moderna, Inc. MRNA will release its fourth-quarter financial results, before the opening bell, on Friday, Feb. 14, 2025.
Insights Into Moderna (MRNA) Q4: Wall Street Projections for Key Metrics
Evaluate the expected performance of Moderna (MRNA) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
2 Biotech Stocks to Buy Hand Over Fist in February
Equity markets performed well in January, as they often do, but as the dust settles on that early-year run, the strategy for long-term investors remains the same: Invest in companies that can perform well over long periods, whether or not they moved in tandem with the market in January. One month of strong (or poor) returns means little in the grand scheme of things.
3 Beaten-Down Stocks That Aren't Worth Buying on the Dip
Buying stocks at significantly reduced valuations can lead to some incredible returns later on. But that doesn't mean that any stock down big is a good buy.
Moderna (MRNA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Moderna (MRNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moderna Poised to Report Q4 Earnings: Is a Beat in the Cards?
When MRNA reports fourth-quarter earnings, investors will likely focus on pipeline updates.
